Trial Profile
Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2022
Price :
$35
*
At a glance
- Drugs Danirixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 08 Oct 2018 Status changed from active, no longer recruiting to completed.
- 14 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Mar 2018 Planned End Date changed from 27 Nov 2018 to 4 Oct 2018.